CY1116176T1 - 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν - Google Patents

2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν

Info

Publication number
CY1116176T1
CY1116176T1 CY20151100336T CY151100336T CY1116176T1 CY 1116176 T1 CY1116176 T1 CY 1116176T1 CY 20151100336 T CY20151100336 T CY 20151100336T CY 151100336 T CY151100336 T CY 151100336T CY 1116176 T1 CY1116176 T1 CY 1116176T1
Authority
CY
Cyprus
Prior art keywords
aryl
derivatives
pharmaceutical compositions
compositions containing
propionic acids
Prior art date
Application number
CY20151100336T
Other languages
Greek (el)
English (en)
Inventor
Marcello Allegretti
Andrea Aramini
Gianluca Bianchini
Maria Candida Cesta
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of CY1116176T1 publication Critical patent/CY1116176T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CY20151100336T 2008-09-18 2015-04-08 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν CY1116176T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164605A EP2166006A1 (en) 2008-09-18 2008-09-18 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP09783167.1A EP2346841B1 (en) 2008-09-18 2009-09-18 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CY1116176T1 true CY1116176T1 (el) 2017-02-08

Family

ID=40291117

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100336T CY1116176T1 (el) 2008-09-18 2015-04-08 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν

Country Status (17)

Country Link
US (1) US8624036B2 (enExample)
EP (2) EP2166006A1 (enExample)
JP (1) JP5571669B2 (enExample)
CN (1) CN102159558B (enExample)
AU (1) AU2009294558B2 (enExample)
CA (1) CA2737099C (enExample)
CY (1) CY1116176T1 (enExample)
DK (1) DK2346841T3 (enExample)
ES (1) ES2534634T3 (enExample)
HR (1) HRP20150395T1 (enExample)
IL (1) IL211683A (enExample)
PL (1) PL2346841T3 (enExample)
PT (1) PT2346841E (enExample)
RU (1) RU2520212C2 (enExample)
SI (1) SI2346841T1 (enExample)
SM (1) SMT201500098B (enExample)
WO (1) WO2010031835A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
KR102191084B1 (ko) * 2013-09-03 2020-12-15 사름 리미티드 약제학적 화합물
AR103399A1 (es) * 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders
SG11201804484YA (en) 2016-01-15 2018-07-30 Dompe Farm Spa Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP3192504A1 (en) 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
US11291641B2 (en) 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3342407A1 (en) * 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8 inihibitors for use in the treatment of some urological disorders
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
CN115397404A (zh) 2020-03-26 2022-11-25 东佩制药股份公司 用于治疗covid-19的cxcl8抑制剂
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
WO2022098822A1 (en) 2020-11-05 2022-05-12 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4406942A1 (en) * 2023-01-26 2024-07-31 Dompe' Farmaceutici S.P.A. Stable monohydrate of df2755a and process for its preparation
EP4563594A1 (en) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1051906A (en) * 1973-10-24 1979-04-03 Shionogi And Co. Thiazole derivatives and production thereof
JPS5537556B2 (enExample) * 1973-12-27 1980-09-29
US4025528A (en) * 1973-10-24 1977-05-24 Shionogi & Co., Ltd. Thiazole derivatives of benzoic and phenylalkanoic acids
JPS565747B2 (enExample) * 1973-10-24 1981-02-06
JPS5629871B2 (enExample) * 1974-05-22 1981-07-10
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
IT1298214B1 (it) 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
DE602005016937D1 (de) * 2004-03-23 2009-11-12 Dompe Pha R Ma Spa Res & Mfg Pharmazeutische zusammensetzung
HRP20161260T1 (hr) * 2005-11-24 2016-11-18 Dompé Farmaceutici S.P.A. Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže
AU2007253424B2 (en) * 2006-05-18 2013-03-07 Dompe' Farmaceutici S.P.A. (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them
ES2394641T3 (es) * 2006-12-19 2013-02-04 Dompe' S.P.A. Ácidos 2-aril-2-fluoropropanoicos y derivados y composiciones farmacéuticas que los contienen
DE602008005488D1 (de) * 2007-10-18 2011-04-21 Dompe Spa (r)-4-(heteroaryl)phenylethylderivate und pharmazeutische zusammensetzungen damit

Also Published As

Publication number Publication date
BRPI0918759A2 (pt) 2015-12-29
EP2346841A2 (en) 2011-07-27
SMT201500098B (it) 2015-07-09
CN102159558B (zh) 2015-01-07
RU2520212C2 (ru) 2014-06-20
CA2737099A1 (en) 2010-03-25
EP2346841B1 (en) 2015-01-14
EP2166006A1 (en) 2010-03-24
WO2010031835A2 (en) 2010-03-25
AU2009294558A1 (en) 2010-03-25
JP5571669B2 (ja) 2014-08-13
CA2737099C (en) 2016-07-05
CN102159558A (zh) 2011-08-17
PT2346841E (pt) 2015-05-07
US20110207785A1 (en) 2011-08-25
JP2012502957A (ja) 2012-02-02
IL211683A0 (en) 2011-06-30
AU2009294558B2 (en) 2014-12-18
PL2346841T3 (pl) 2015-07-31
SI2346841T1 (sl) 2015-07-31
DK2346841T3 (en) 2015-04-20
IL211683A (en) 2014-01-30
RU2011114992A (ru) 2012-10-27
WO2010031835A3 (en) 2010-06-24
ES2534634T3 (es) 2015-04-27
HRP20150395T1 (hr) 2015-06-19
US8624036B2 (en) 2014-01-07

Similar Documents

Publication Publication Date Title
CY1116176T1 (el) 2-αρυλο-προπιονικα οξεα και παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
CY1124206T1 (el) Αναστολεις πυριδοπυριμδινονης cdk2/4/6
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
MX381953B (es) Sales de derivados de piperazina obtenidas por adicion de acidos.
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
MX2021004000A (es) Derivados de piperidina.
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
EA201101026A1 (ru) Ингибиторы бета-секретазы
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
MX386166B (es) Derivados de piperidina 1,4-sustituidos.
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1116548T1 (el) Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων
WO2012138955A3 (en) CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS
BR112013016595A2 (pt) inibidores de neprilisina
CY1120515T1 (el) Παραγωγο κυκλοαλκυλικο οξεος, μεθοδος παρασκευης και φαρμακευτικη εφαρμογη αυτου
EA201990455A1 (ru) КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
UY33200A (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos